Patent number: 6632814
Abstract: The invention is directed to physiologically active compounds of formula (I):
wherein
R1 represents R3—Z3—, R3—L2—R4—Z3—, R3—L3—Ar1—L4—Z3— or R3—L3—Ar1—L2—R4—Z3—;
R2 represents hydrogen, halogen, lower alkyl or lower alkoxy;
A1 represents a straight chain C2-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by —ZR6, —NY1Y2, —CO2R6 or —C(═O)—NY1Y2;
L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, —S(O)mR9, R3, —C(═O)—R3, —C(═O)—OR3, —N(R8)—C(═O)—R9, —N(R8)—C(═O)—OR9, —N(R
Type:
Grant
Filed:
August 23, 2000
Date of Patent:
October 14, 2003
Assignees:
Aventis Pharma Ltd., Aventis Pharmaceuticals Recherche Developpment
Inventors:
Jean-Dominique Bourzat, Alain Commercon, Bruno Jacques Christophe Filoche, Neil Victor Harris, Thomas David Pallin, Keith Alfred James Stuttle
